Immunotherapy-TACE Regimen Boosts PFS in Unresectable Liver Cancer

(MedPage Today) -- SAN FRANCISCO -- Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC), according...